Contineum Therapeutics, Inc. (CTNM) · Nov 3, 2026 · Earnings
Miss — EPS $(0.49) vs ~$0.45 consensus
Contineum’s Q3 earnings missed consensus as spending rose, but the company expanded its lead IPF trial to more than 100 sites.
Contineum is a clinical-stage biotech now concentrated around PIPE-791 and its global Phase 2 PROPEL-IPF trial for idiopathic pulmonary fibrosis; management has been prioritizing that program while keeping cash resources sufficient through mid-2029.
The quarter itself was a modest earnings miss, but not the main business signal. Net loss widened to $18.7 million from $12.8 million, while diluted loss per share was $(0.49) versus a published consensus of roughly $(0.45). Research and development spending rose 45% to $16.0 million as PIPE-791 IPF work accelerated, so the miss reflects heavier investment in the lead program rather than a new revenue problem.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss (Financial Statements) | $(18.7)M | $(12.8)M | |
| Diluted loss per share (Financial Statements) | $(0.49) | $(0.45) | $(0.45) |
| R&D expense (Financial Statements) | $16.0M (+45%) | $11.0M | |
| G&A expense (Financial Statements) | $5.0M (+26%) | $3.9M | |
| Cash and equivalents (Balance Sheet) | $75.2M | $75.6M at Dec. 31, 2025 | |
| Cash plus marketable securities (Balance Sheet) | $244.5M | $262.9M at Dec. 31, 2025 |
The operating update is better than the headline EPS result. PROPEL-IPF has expanded from more than 55 sites in eight countries at the prior quarter to more than 100 sites in 16 countries, showing that the global trial is moving into a broader execution phase rather than stalling. The filing does not provide patient-enrollment numbers or a revised completion date, so the site count is evidence of infrastructure progress, not yet proof of faster clinical delivery. 〔0〕
The balance sheet still supports the current plan. Cash, cash equivalents and marketable securities totaled roughly $244.5 million at September 30, down from $262.9 million at year-end, while the company reiterated a cash runway through mid-2029. That leaves the trial funded on the company’s stated plan, although the higher quarterly operating loss shows that the runway depends on continued spending discipline. 〔1〕
Bottom line: The quarter missed modestly on EPS because Contineum is spending more to advance PIPE-791, but the more important development is tangible expansion of the lead IPF trial. This slightly improves the operating story even though the financial scorecard was weaker than expected.
PROPEL-IPF enrollment and Phase 2 trial completion
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!